Developmental Expression of the Major Human Hepatic CYP3A Enzymes
暂无分享,去创建一个
Ronald N. Hines | S. B. Koukouritaki | J. Manro | J. Stevens | R. Hines | Jason R. Manro | Peter J Tandler | Chungang Gu | Jeffrey C. Stevens | Sevasti B. Koukouritaki | Peter J. Tandler | Matthew J. Zaya | Chungang Gu | M. J. Zaya
[1] W. Pierce,et al. Metabolism of DHEA by cytochromes P450 in rat and human liver microsomal fractions. , 2001, Archives of biochemistry and biophysics.
[2] N. Cheung,et al. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. , 1996, The Journal of clinical endocrinology and metabolism.
[3] R. Edwards,et al. Cytochrome P450 3A Expression in the Human Fetal Liver: Evidence that CYP3A5 Is Expressed in Only a Limited Number of Fetal Livers , 2001, Neonatology.
[4] F. Guengerich. Oxidation-reduction properties of rat liver cytochromes P-450 and NADPH-cytochrome p-450 reductase related to catalysis in reconstituted systems. , 1983, Biochemistry.
[5] M. Relling,et al. Human cytochrome P450 maximal activities in pediatric versus adult liver. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[6] G. Kearns,et al. Cytochrome P450 3A , 1999, Clinical pharmacokinetics.
[7] G. Chabot,et al. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. , 2002, Biochemical pharmacology.
[8] L Hendeles,et al. Theophylline A “State of the Art” Review , 1983, Pharmacotherapy.
[9] F. Guengerich,et al. Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.
[10] B. Ring,et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[11] J B Houston,et al. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.
[12] L. Wienkers,et al. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[13] D. Greenblatt,et al. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. , 2001, The Journal of pharmacology and experimental therapeutics.
[14] J. George,et al. Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. , 1998, The Journal of clinical endocrinology and metabolism.
[15] S. Hirschfeld. Dysregulation of growth and development in HIV-infected children. , 1996, The Journal of nutrition.
[16] G. Kearns,et al. The challenges of delivering pharmacogenomics into clinical pediatrics , 2002, The Pharmacogenomics Journal.
[17] E. Schuetz,et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.
[18] H. Glaeser,et al. Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine* , 2002, The Journal of Biological Chemistry.
[19] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[20] S. Wrighton,et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.
[21] J S Harmatz,et al. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[22] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[23] J. Magny,et al. Population pharmacokinetics of midazolam in neonates , 1994, Clinical pharmacology and therapeutics.
[24] P. Watkins,et al. THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.
[25] T. Aoyama,et al. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.
[26] T. Shimada,et al. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[27] S. Imaoka,et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. , 1997, Life sciences.
[28] A. Berkenstam,et al. Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. , 2001, Biochemical and biophysical research communications.
[29] H. Yamazaki,et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[30] J. Brockmöller,et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[31] E. Schuetz,et al. Cisapride: A potential model substrate to assess cytochrome P4503A4 activity in vivo , 2003, Clinical pharmacology and therapeutics.
[32] H. Yamazaki,et al. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. , 2002, Protein expression and purification.
[33] S. Yamaguchi,et al. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. , 1999, Biochemical pharmacology.
[34] S. Wrighton,et al. Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. , 1989, Archives of biochemistry and biophysics.
[35] A. Rettie,et al. Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression , 2002, Pediatric Research.
[36] A. Nafziger,et al. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.
[37] T. Kamataki,et al. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. , 1987, The Journal of biological chemistry.
[38] T. Cresteil,et al. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.
[39] P. Watkins,et al. Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.